ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGX

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the announcement on May 1, 2024, that the collaboration agreement with Moderna was mutually terminated [4] - Investors are encouraged to join the class action and can do so without any out-of-pocket fees through a contingency fee arrangement [1][2] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked highly for securities class action settlements [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]